Sydney, Australia 10 July 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at Royal North Shore Hospital in Sydney has been completed and recruitment has commenced for its SARTATE™ clinical trial.
Clarity’s SARTATE™ trial is a Peptide Receptor Radionuclide Therapy clinical trial of patients with meningioma using Copper-64 SARTATE™ for imaging and Copper-67 SARTATE™ for therapy. It is a single-centre, open-label, non-randomised Phase 1-2a theranostic (i.e. diagnostic and therapy) clinical trial in 6 patients that is being led by Dr Geoffrey P Schembri from Royal North Shore Hospital.
Meningioma is the most frequent type of primary brain cancer that accounts for 36% of all intracranial tumours. The incidence rate is 7.61/100,000 with a male-to-female ratio of 1:23. The 5-year overall survival (OS) rate is estimated to be 70% for benign meningiomas, 75% for atypical meningiomas and 55% for patients with anaplastic tumours.
Dr Alan Taylor, Clarity’s Executive Chairman, commented on the site activation “We are very excited to commence this trial at Royal North Shore Hospital. Not only are the results important to better treat this patient population, the data will also be used to progress SARTATE™ into additional clinical trials for the treatment of children with neuroblastoma, an aggressive childhood cancer. Clarity’s ultimate goal is to not only improve survival rates of children and adults with cancer, but also minimise side effects and improve overall patient outcomes.”
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
